Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases

Neuroscience

Volumn 145, Issue 4, 2007, Pages 1233-1248

  Trushina, E ^a   McMurray, C T ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Friedreich ataxia; Huntington's disease; mitochondria; neurodegeneration; oxidative damage; xeroderma pigmentosum

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTIOXIDANT; CELL NUCLEUS DNA; CREATINE; CYSTAMINE; ESSENTIAL FATTY ACID; FREE RADICAL; MERCAPTAMINE; MITOCHONDRIAL DNA; REMACEMIDE; RILUZOLE; THIOCTIC ACID; UBIQUINONE;

CLINICAL FEATURE; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; MEMBRANE DAMAGE; MUTATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; XERODERMA PIGMENTOSUM;

ANIMALS; DNA DAMAGE; ENERGY METABOLISM; FRIEDREICH ATAXIA; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS; XERODERMA PIGMENTOSUM;

EID: 34247158550     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.10.056     Document Type: Review

References (173)

1. Adamec J., Rusnak F., Owen W.G., Naylor S., Benson L.M., Gacy A.M., and Isaya G. Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am J Hum Genet 67 (2000) 549-562
2. Al-Karadaghi S., Franco R., Hansson M., Shelnutt J.A., Isaya G., and Ferreira G.C. Chelatases: distort to select?. Trends Biochem Sci 31 (2006) 135-142
3. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., and Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 8 (2001) 479-491
4. Arenas J., Campos Y., Ribacoba R., Martin M.A., Rubio J.C., Ablanedo P., and Cabello A. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol 43 (1998) 397-400
5. Bae B.I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S.D., Moran T.H., Montell C., Ross C.A., Snyder S.H., and Sawa A. p53 Mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 (2005) 29-41
6. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Ann Neurol 31 (1992) 119-130
7. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58 (2005) 495-505
8. Beal M.F., Ferrante R.J., Swartz K.J., and Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11 (1991) 1649-1659
9. Benchoua A., Trioulier Y., Zala D., Gaillard M.C., Lefort N., Dufour N., Saudou F., Elalouf J.M., Hirsch E., Hantraye P., Deglon N., and Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17 (2006) 1652-1663
10. Bezprozvanny I., and Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun 322 (2004) 1310-1317
11. Bjelland S., and Seeberg E. Mutagenicity, toxicity and repair of DNA base damage induced by oxidation. Mutat Res 531 (2003) 37-80
12. Bolanos J.P., Almeida A., Fernandez E., Medina J.M., Land J.M., Clark J.B., and Heales S.J. Potential mechanisms for nitric oxide-mediated impairment of brain mitochondrial energy metabolism. Biochem Soc Trans 25 (1997) 944-949
13. Bootsma D., Kraemer K.H., Cleaver J.E., and Hoeijmakers J.H.J. Nucleotide excision repair syndromes: xeroderma pigmentosum, cockayne syndrome, and trichothiodystrophy. In: Scriver C., Beaudet A.L., and Sly W.S. (Eds). The metabolic and molecular bases of inherited disease Vol. 3 (2005), McGraw-Hill Companies 137-150
14. Borrell-Pages M., Canals J.M., Cordelieres F.P., Parker J.A., Pineda J.R., Grange G., Bryson E.A., Guillermier M., Hirsch E., Hantraye P., Cheetham M.E., Neri C., Alberch J., Brouillet E., Saudou F., and Humbert S. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116 (2006) 1410-1424
15. Borrello S., De Leo M.E., Landriscina M., Palazzotti B., and Galeotti T. Diethyldithiocarbamate treatment up regulates manganese superoxide dismutase gene expression in rat liver. Biochem Biophys Res Commun 220 (1996) 546-552
16. Borrello S., De Leo M.E., Wohlrab H., and Galeotti T. Manganese deficiency and transcriptional regulation of mitochondrial superoxide dismutase in hepatomas. FEBS Lett 310 (1992) 249-254
17. Browne S.E., and Beal M.F. The energetics of Huntington's disease. Neurochem Res 29 (2004) 531-546
18. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., and Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41 (1997) 646-653
19. Brustovetsky N., LaFrance R., Purl K.J., Brustovetsky T., Keene C.D., Low W.C., and Dubinsky J.M. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's disease. J Neurochem 93 (2005) 1361-1370
20. Bulteau A.L., O'Neill H.A., Kennedy M.C., Ikeda-Saito M., Isaya G., and Szweda N. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305 (2004) 242-245
21. Campuzano V., Montermini L., Molto M.D., Pianese L., Cossee M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A., Zara F., Canizares J., Koutnikova H., Bidichandani S.I., Gellera C., Brice A., Trouillas P., De Michele G., Filla A., De Frutos R., Palau F., Patel P.I., Di Donato S., Mandel J.L., Cocozza S., Koenig M., and Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
22. Cantuti-Castelvetri I., Lin M.T., Zheng K., Keller-McGandy C.E., Betensky R.A., Johns D.R., Beal M.F., Standaert D.G., and Simon D.K. Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging 26 (2005) 1343-1355
23. Castro L., Rodriguez M., and Radi R. Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J Biol Chem 269 (1994) 29409-29415
24. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., and Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 24 (2001) 182-188
25. Cavadini P., O'Neill H.A., Benada O., and Isaya G. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum Mol Genet 11 (2002) 217-227
26. Chang D.T., Rintoul G.L., Pandipati S., and Reynolds I.J. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 22 (2006) 388-400
27. Chantrel-Groussard K., Geromel V., Puccio H., Koenig M., Munnich A., Rötig A., and Rustin P. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet 10 (2001) 2061-2067
28. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., and Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13 (2004) 1407-1420
29. Ciammola A., Sassone J., Alberti L., Meola G., Mancinelli E., Russo M.A., Squitieri F., and Silani V. Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ 13 (2006) 2068-2078
30. Cleaver J.E. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 5 (2005) 564-573
31. Clifford J.J., Drago J., Natoli A.L., Wong J.Y., Kinsella A., Waddington J.L., and Vaddadi K.S. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 109 (2002) 81-88
32. Cole N.B., Murphy D.D., Grider T., Rueter S., Brasaemle D., and Nussbaum R.L. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem 277 (2002) 6344-6352
33. Cossee M., Durr A., Schmitt M., Dahl N., Trouillas P., Allinson P., Kostrzewa M., Nivelon-Chevallier A., Gustavson K.H., Kohlschutter A., Muller U., Mandel J.L., Brice A., Koenig M., Cavalcanti F., Tammaro A., De Michele G., Filla A., Cocozza S., Labuda M., Montermini L., Poirier J., and Pandolfo M. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45 (1999) 200-206
34. Daum G. Lipids of mitochondria. Biochim Biophys Acta 822 (1985) 1-42
35. Dip R., Camenisch U., and Naegeli H. Mechanisms of DNA damage recognition and strand discrimination in human nucleotide excision repair. DNA Repair (Amst) 3 (2004) 1409-1423
36. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., and Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296 (2002) 2238-2243
37. El-Khamisy S.F., and Caldecott K.W. TDP1-dependent DNA single-strand break repair and neurodegeneration. Mutagenesis 21 4 (2006) 219-224
38. Emond M., Lepage G., Vanasse M., and Pandolfo M. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 55 (2000) 1752-1753
39. Engelender S., Sharp A.H., Colomer V., Tokito M.K., Lanahan A., Worley P., Holzbaur E.L., and Ross C.A. Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. Hum Mol Genet 6 (1997) 2205-2212
40. Esposito L.A., Kokoszka J.E., Waymire K.G., Cottrell B., MacGregor G.R., and Wallace D.C. Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene. Free Radic Biol Med 28 (2000) 754-766
41. Feng Z., Jin S., Zupnick A., Hoh J., de Stanchina E., Lowe S., Prives C., and Levine A.J. p53 Tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25 (2006) 1-7
42. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., and Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22 (2002) 1592-1599
43. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., and Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 20 (2000) 4389-4397
44. Floyd R.A., West M.S., Eneff K.L., Schneider J.E., Wong P.K., Tingey D.T., and Hogsett W.E. Conditions influencing yield and analysis of 8-hydroxy-2′-deoxyguanosine in oxidatively damaged DNA. Anal Biochem 188 (1990) 155-158
45. Friedberg E.C. DNA damage and repair. Nature 421 (2003) 436-440
46. Gacy A.M., Goellner G.M., Spiro C., Chen X., Gupta G., Bradbury E.M., Dyer R.B., Mikesell M.J., Yao J.Z., Johnson A.J., Richter A., Melancon S.B., and McMurray C.T. GAA instability in Friedreich's ataxia shares a common, DNA-directed and intraallelic mechanism with other trinucleotide diseases. Mol Cell 1 (1998) 583-593
47. Gakh O., Park S., Liu G., Macomber L., Imlay J.A., Ferreira G.C., and Isaya G. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet 15 (2006) 467-479
48. Gardner P.R., and Fridovich I. Superoxide sensitivity of the Escherichia coli 6-phosphogluconate dehydratase. J Biol Chem 266 (1991) 1478-1483
49. Gardner P.R., Raineri I., Epstein L.B., and White C.W. Superoxide radical and iron modulate aconitase activity in mammalian cells. J Biol Chem 270 (1995) 13399-13405
50. Gatchel J.R., and Zoghbi H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 6 (2005) 743-755
51. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., and Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118 (2004) 127-138
52. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., Gusella J.F., Wheeler V.C., Persichetti F., and MacDonald M.E. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 12 (2003) 497-508
53. Gizatullina Z.Z., Lindenberg K.S., Harjes P., Chen Y., Kosinski C.M., Landwehrmeyer B.G., Ludolph A.C., Striggow F., Zierz S., and Gellerich F.N. Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann Neurol 59 (2006) 407-411
54. Goswami A., Dikshit P., Mishra A., Mulherkar S., Nukina N., and Jana N.R. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun 342 (2006) 184-190
55. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., Warby S.C., Doty C.N., Roy S., Wellington C.L., Leavitt B.R., Raymond L.A., Nicholson D.W., and Hayden M.R. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125 (2006) 1179-1191
56. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., and Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39 (1996) 385-389
57. Guidetti P., Charles V., Chen E.Y., Reddy P.H., Kordower J.H., Whetsell Jr. W.O., Schwarcz R., and Tagle D.A. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 169 (2001) 340-350
58. Guidot D.M., McCord J.M., Wright R.M., and Repine J.E. Absence of electron transport (Rho 0 state) restores growth of a manganese-superoxide dismutase-deficient Saccharomyces cerevisiae in hyperoxia. Evidence for electron transport as a major source of superoxide generation in vivo. J Biol Chem 268 (1993) 26699-26703
59. Gunawardena S., Her L.S., Brusch R.G., Laymon R.A., Niesman I.R., Gordesky-Gold B., Sintasath L., Bonini N.M., and Goldstein L.S. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40 (2003) 25-40
60. Hanawalt P.C., Ford J.M., and Lloyd D.R. Functional characterization of global genomic DNA repair and its implications for cancer. Mutat Res 544 (2003) 107-114
61. Handley O.J., Naji J.J., Dunnett S.B., and Rosser A.E. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci (Lond) 110 (2006) 73-88
62. Harjes P., and Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28 (2003) 425-433
63. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 11 (1956) 298-300
64. Hazra T.K., Hill J.W., Izumi T., and Mitra S. Multiple DNA glycosylases for repair of 8-oxoguanine and their potential in vivo functions. Prog Nucleic Acid Res Mol Biol 68 (2001) 193-205
65. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., Como P., Zimmerman C., Lin M., Zhang L., Ulug A.M., Beal M.F., Matson W., Bogdanov M., Ebbel E., Zaleta A., Kaneko Y., Jenkins B., Hevelone N., Zhang H., Yu H., Schoenfeld D., Ferrante R., and Rosas H.D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology 66 (2006) 250-252
66. Hilditch-Maguire P., Trettel F., Passani L.A., Auerbach A., Persichetti F., and MacDonald M.E. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 9 (2000) 2789-2797
67. Hoch F.L. Cardiolipins and biomembrane function. Biochim Biophys Acta 1113 (1992) 71-133
68. Horton T.M., Graham B.H., Corral-Debrinski M., Shoffner J.M., Kaufman A.E., Beal M.F., and Wallace D.C. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology 45 (1995) 1879-1883
69. Huang Z., Hou Q., Cheung N.S., and Li Q.T. Neuronal cell death caused by inhibition of intracellular cholesterol trafficking is caspase dependent and associated with activation of the mitochondrial apoptosis pathway. J Neurochem 97 (2006) 280-291
70. Huie R.E., and Padmaja S. The reaction of no with superoxide. Free Radic Res Commun 18 (1993) 195-199
71. Irwin C.C., Wexler N.S., Young A.B., Ozelius L.J., Penney J.B., Shoulson I., Snodgrass S.R., Ramos-Arroyo M.A., Sanchez-Ramos J., Penchaszadeh G.K., et al. The role of mitochondrial DNA in Huntington's disease. J Mol Neurosci 1 (1989) 129-136
72. Jenkins B.G., Rosas H.D., Chen Y.C., Makabe T., Myers R., MacDonald M., Rosen B.R., Beal M.F., and Koroshetz W.J. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 50 (1998) 1357-1365
73. Jo E., Darabie A.A., Han K., Tandon A., Fraser P.E., and McLaurin J. alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. Eur J Biochem 271 (2004) 3180-3189
74. Karthikeyan G., Lewis L.K., and Resnick M.A. The mitochondrial protein frataxin prevents nuclear damage. Hum Mol Genet 11 (2002) 1351-1362
75. Karthikeyan G., Santos J.H., Graziewicz M.A., Copeland W.C., Isaya G., Van Houten B., and Resnick M.A. Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum Mol Genet 12 (2003) 3331-3342
76. Kegel K.B., Kim M., Sapp E., McIntyre C., Castano J.G., Aronin N., and DiFiglia M. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 20 (2000) 7268-7278
77. Kegel K.B., Meloni A.R., Yi Y., Kim Y.J., Doyle E., Cuiffo B.G., Sapp E., Wang Y., Qin Z.H., Chen J.D., Nevins J.R., Aronin N., and DiFiglia M. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 277 (2002) 7466-7476
78. Kegel K.B., Sapp E., Yoder J., Cuiffo B., Sobin L., Kim Y.J., Qin Z.H., Hayden M.R., Aronin N., Scott D.L., Isenberg G., Goldmann W.H., and DiFiglia M. Huntingtin associates with acidic phospholipids at the plasma membrane. J Biol Chem 280 (2005) 36464-36473
79. Keyer K., and Imlay J.A. Superoxide accelerates DNA damage by elevating free-iron levels. Proc Natl Acad Sci U S A 93 (1996) 13635-13640
80. King M.P., and Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246 (1989) 500-503
81. Koroshetz W.J., Jenkins B.G., Rosen B.R., and Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 41 (1997) 160-165
82. Kuo C.F., Mashino T., and Fridovich I. alpha, beta-Dihydroxyisovalerate dehydratase. A superoxide-sensitive enzyme. J Biol Chem 262 (1987) 4724-4727
83. Kruman I.I., Wersto R.P., Cardozo-Pelaez F., Smilenov L., Chan S.L., Chrest F.J., Emokpae Jr. R., Gorospe M., and Mattson M.P. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 19 (2004) 549-561
84. Leavitt B.R., Guttman J.A., Hodgson J.G., Kimel G.H., Singaraja R., Vogl A.W., and Hayden M.R. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 68 (2001) 313-324
85. Leavitt B.R., Raamsdonk J.M., Shehadeh J., Fernandes H., Murphy Z., Graham R.K., Wellington C.L., Raymond L.A., and Hayden M.R. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 96 (2006) 1121-1129
86. Lee S.T., and Kim M. Aging and neurodegeneration. Molecular mechanisms of neuronal loss in Huntington's disease. Mech Ageing Dev 127 (2006) 432-435
87. Li S.H., Cheng A.L., Zhou H., Lam S., Rao M., Li H., and Li X.J. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22 (2002) 1277-1287
88. Li S.H., Gutekunst C.A., Hersch S.M., and Li X.J. Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 18 (1998) 1261-1269
89. Li S.H., and Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20 (2004) 146-154
90. Lill R., and Muhlenhoff U. Iron-sulfur-protein biogenesis in eukaryotes. Trends Biochem Sci 30 (2005) 133-141
91. Lodi R., Cooper J.M., Bradley J.L., Manners D., Styles P., Taylor D.J., and Schapira A.H. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A 96 (1999) 11492-11495
92. Lodi R., Schapira A.H., Manners D., Styles P., Wood N.W., Taylor D.J., and Warner T.T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 48 (2000) 72-76
93. Lodi R., Tonon C., Calabrese V., and Schapira A.H. Friedreich's ataxia: From disease mechanisms to therapeutic interventions. Antioxid Redox Signal 8 (2006) 438-443
94. MacMillan-Crow L.A., Crow J.P., and Thompson J.A. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 37 (1998) 1613-1622
95. Majumder P., Chattopadhyay B., Mazumder A., Das P., and Bhattacharyya N.P. Induction of apoptosis in cells expressing exogenous Hippi, a molecular partner of huntingtin-interacting protein Hip1. Neurobiol Dis 22 (2006) 242-256
96. Mann V.M., Cooper J.M., Javoy-Agid F., Agid Y., Jenner P., and Schapira A.H. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336 (1990) 749
97. Manna S.K., Zhang H.J., Yan T., Oberley L.W., and Aggarwal B.B. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem 273 (1998) 13245-13254
98. Mao Z., Choo Y.S., and Lesort M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur J Neurosci 23 (2006) 1701-1710
99. Mariani E., Polidori M.C., Cherubini A., and Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 827 (2005) 65-75
100. Mattson M.P. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci 1012 (2004) 37-50
101. McCormick M.L., Buettner G.R., and Britigan B.E. Endogenous superoxide dismutase levels regulate iron-dependent hydroxyl radical formation in Escherichia coli exposed to hydrogen peroxide. J Bacteriol 180 (1998) 622-625
102. McMurray C.T. To die or not to die: DNA repair in neurons. Mutant Res 577 (2005) 260-274
103. Michalik A., and Van Broeckhoven C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 12 Spec No 2 (2003) R173-R186
104. Michiels C., Raes M., Toussaint O., and Remacle J. Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med 17 (1994) 235-248
105. Milakovic T., and Johnson G.V. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280 (2005) 30773-30782
106. Montermini L., Andermann E., Labuda M., Richter A., Pandolfo M., Cavalcanti F., Pianese L., Iodice L., Farina G., Monticelli A., Turano M., Filla A., De Michele G., and Cocozza S. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum Mol Genet 6 (1997) 1261-1266
107. Montermini L., Kish S.J., Jiralerspong S., Lamarche J.B., and Pandolfo M. Somatic mosaicism for Friedreich's ataxia GAA triplet repeat expansions in the central nervous system. Neurology 49 (1997) 606-610
108. Muhlenhoff U., Richhardt N., Ristow M., Kispal G., and Lill R. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet 11 (2002) 2025-2036
109. Nucifora Jr. F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., and Ross C.A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291 (2001) 2423-2428
110. Ohshima K., Montermini L., Wells R.D., and Pandolfo M. Inhibitory effects of expanded GAA. TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem 273 (1998) 14588-14595
111. Ono M., Kohda H., Kawaguchi T., Ohhira M., Sekiya C., Namiki M., Takeyasu A., and Taniguchi N. Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells. Biochem Biophys Res Commun 182 (1992) 1100-1107
112. Panov A.V., Burke J.R., Strittmatter W.J., and Greenamyre J.T. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch Biochem Biophys 410 (2003) 1-6
113. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., and Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5 (2002) 731-736
114. Park S., Gakh O., O'Neill H.A., Mangravita A., Nichol H., Ferreira G.C., and Isaya G. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J Biol Chem 278 (2003) 31340-31351
115. Perez-Severiano F., Rios C., and Segovia J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res 862 (2000) 234-237
116. Perutz M.F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci 24 (1999) 58-63
117. Piemonte F., Pastore A., Tozzi G., Tagliacozzi D., Santorelli F.M., Carrozzo R., Casali C., Damiano M., Federici G., and Bertini E. Glutathione in blood of patients with Friedreich's ataxia. Eur J Clin Invest 31 (2001) 1007-1011
118. Polidori M.C., Mecocci P., Browne S.E., Senin U., and Beal M.F. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci Lett 272 (1999) 53-56
119. Poulsen H.E. Oxidative DNA modifications. Exp Toxicol Pathol 57 Suppl 1 (2005) 161-169
120. Puccio H., Simon D., Cossee M., Criqui-Filipe P., Tiziano F., Melki J., Hindelang C., Matyas R., Rustin P., and Koenig M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27 (2001) 181-186
121. Puranam K.L., Wu G., Strittmatter W.J., and Burke J.R. Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. Biochem Biophys Res Commun 341 (2006) 607-613
122. Radi R., Rodriguez M., Castro L., and Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 308 (1994) 89-95
123. Radisky D.C., Babcock M.C., and Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem 274 (1999) 4497-4499
124. Rao V.R., and Finkbeiner S. Secrets of a secretase: N-cadherin proteolysis regulates CBP function. Cell 114 (2003) 533-535
125. Read M.A., Whitley M.Z., Gupta S., Pierce J.W., Best J., Davis R.J., and Collins T. Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 272 (1997) 2753-2761
126. Reddy P.H. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 96 (2006) 1-13
127. Rigamonti D., Bauer J.H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., Cooper J.K., Ross C.A., Govoni S., Vincenz C., and Cattaneo E. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20 (2000) 3705-3713
128. Ross C.A., and Poirier M.A. Protein aggregation and neurodegenerative disease. Nat Med 10 Suppl (2004) S10-S17
129. Rötig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., Munnich A., and Rustin P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17 (1997) 215-217
130. Ruan Q., Lesort M., MacDonald M.E., and Johnson G.V. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet 13 (2004) 669-681
131. Saft C., Zange J., Andrich J., Muller K., Lindenberg K., Landwehrmeyer B., Vorgerd M., Kraus P.H., Przuntek H., and Schols L. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 20 (2005) 674-679
132. Sakamoto N., Ohshima K., Montermini L., Pandolfo M., and Wells R.D. Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem 276 (2001) 27171-27177
133. Sawa A. Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria?. J Mol Med 79 (2001) 375-381
134. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler Jr. J.F., Greenamyre J.T., Snyder S.H., and Ross C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5 (1999) 1194-1198
135. Seong I.S., Ivanova E., Lee J.M., Choo Y.S., Fossale E., Anderson M., Gusella J.F., Laramie J.M., Myers R.H., Lesort M., and MacDonald M.E. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14 (2005) 2871-2880
136. Schiefer J., Landwehrmeyer G.B., Luesse H.G., Sprunken A., Puls C., Milkereit A., Milkereit E., and Kosinski C.M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov Disord 17 (2002) 748-757
137. Schilling G., Coonfield M.L., Ross C.A., and Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 315 (2001) 149-153
138. Schulz J.B., Dehmer T., Schols L., Mende H., Hardt C., Vorgerd M., Burk K., Matson W., Dichgans J., Beal M.F., and Bogdanov M.B. Oxidative stress in patients with Friedreich ataxia. Neurology 55 (2000) 1719-1721
139. Shi X., Dong Z., Huang C., Ma W., Liu K., Ye J., Chen F., Leonard S.S., Ding M., Castranova V., and Vallyathan V. The role of hydroxyl radical as a messenger in the activation of nuclear transcription factor NF-kappaB. Mol Cell Biochem 194 (1999) 63-70
140. Shimohata T., Onodera O., and Tsuji S. Interaction of expanded polyglutamine stretches with nuclear transcription factors leads to aberrant transcriptional regulation in polyglutamine diseases. Neuropathology 20 (2000) 326-333
141. Shoichet S.A., Baumer A.T., Stamenkovic D., Sauer H., Pfeiffer A.F., Kahn C.R., Muller-Wieland D., Richter C., and Ristow M. Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation in vitro. Hum Mol Genet 11 (2002) 815-821
142. Singh K.K. Mitochondria damage checkpoint, aging, and cancer. Ann N Y Acad Sci 1067 (2006) 182-190
143. Sjogren M., Mielke M., Gustafson D., Zandi P., and Skoog I. Cholesterol and Alzheimer's disease: is there a relation?. Mech Ageing Dev 127 (2006) 138-147
144. Squitieri F., Cannella M., Sgarbi G., Maglione V., Falleni A., Lenzi P., Baracca A., Cislaghi G., Saft C., Ragona G., Russo M.A., Thompson L.M., Solaini G., and Fornai F. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev 127 (2006) 217-220
145. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., and Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97 (2000) 6763-6768
146. Sugars K.L., Brown R., Cook L.J., Swartz J., and Rubinsztein D.C. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem 279 (2004) 4988-4999
147. Suopanki J., Gotz C., Lutsch G., Schiller J., Harjes P., Herrmann A., and Wanker E.E. Interaction of huntingtin fragments with brain membranes: clues to early dysfunction in Huntington's disease. J Neurochem 96 (2006) 870-884
148. Swerdlow R.H., Parks J.K., Cassarino D.S., Shilling A.T., Bennett Jr. J.P., Harrison M.B., and Parker Jr. W.D. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochem Biophys Res Commun 261 (1999) 701-704
149. Szebenyi G., Morfini G.A., Babcock A., Gould M., Selkoe K., Stenoien D.L., Young M., Faber P.W., MacDonald M.E., McPhaul M.J., and Brady S.T. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40 (2003) 41-52
150. Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P., Schapira A.H., and Warner T.T. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 64 (2005) 1655-1656
151. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., and Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45 (1999) 25-32
152. Takahashi K., Avissar N., Whitin J., and Cohen H. Purification and characterization of human plasma glutathione peroxidase: a selenoglycoprotein distinct from the known cellular enzyme. Arch Biochem Biophys 256 (1987) 677-686
153. Tan G., Chen L.S., Lonnerdal B., Gellera C., Taroni F.A., and Cortopassi G.A. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum Mol Genet 10 (2001) 2099-2107
154. Tang T.S., Slow E., Lupu V., Stavrovskaya I.G., Sugimori M., Llinas R., Kristal B.S., Hayden M.R., and Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 102 (2005) 2602-2607
155. Tang T.S., Tu H., Chan E.Y., Maximov A., Wang Z., Wellington C.L., Hayden M.R., and Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39 (2003) 227-239
156. Tang T.S., Tu H., Orban P.C., Chan E.Y., Hayden M.R., and Bezprozvanny I. HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca release in primary culture of striatal medium spiny neurons. Eur J Neurosci 20 (2004) 1779-1787
157. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
158. Trushina E., Dyer R.B., Badger II J.D., Ure D., Eide L., Tran D.D., Vrieze B.T., Legendre-Guillemin V., McPherson P.S., Mandavilli B.S., Van Houten B., Zeitlin S., McNiven M., Aebersold R., Hayden M., Parisi J.E., Seeberg E., Dragatsis I., Doyle K., Bender A., Chacko C., and McMurray C.T. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 24 (2004) 8195-8209
159. Trushina E., Heldebrant M.P., Perez-Terzic C.M., Bortolon R., Kovtun I.V., Badger II J.D., Terzic A., Estevez A., Windebank A.J., Dyer R.B., Yao J., and McMurray C.T. Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proc Natl Acad Sci U S A 100 (2003) 12171-12176
160. Tukamoto T., Nukina N., Ide K., and Kanazawa I. Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Brain Res Mol Brain Res 51 (1997) 8-14
161. Valenza M., Rigamonti D., Goffredo D., Zuccato C., Fenu S., Jamot L., Strand A., Tarditi A., Woodman B., Racchi M., Mariotti C., Di Donato S., Corsini A., Bates G., Pruss R., Olson J.M., Sipione S., Tartari M., and Cattaneo E. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 25 (2005) 9932-9939
162. van Dellen A., Grote H.E., and Hannan A.J. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease. Clin Exp Pharmacol Physiol 32 (2005) 1007-1019
163. van Loon A.P., Pesold-Hurt B., and Schatz G. A yeast mutant lacking mitochondrial manganese-superoxide dismutase is hypersensitive to oxygen. Proc Natl Acad Sci U S A 83 (1986) 3820-3824
164. Visner G.A., Dougall W.C., Wilson J.M., Burr I.A., and Nick H.S. Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1, and tumor necrosis factor. Role in the acute inflammatory response. J Biol Chem 265 (1990) 2856-2864
165. Vorgerd M., Schols L., Hardt C., Ristow M., Epplen J.T., and Zange J. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord 10 (2000) 430-435
166. Waelter S., Scherzinger E., Hasenbank R., Nordhoff E., Lurz R., Goehler H., Gauss C., Sathasivam K., Bates G.P., Lehrach H., and Wanker E.E. The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. Hum Mol Genet 10 (2001) 1807-1817
167. White J.K., Auerbach W., Duyao M.P., Vonsattel J.P., Gusella J.F., Joyner A.L., and MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17 (1997) 404-410
168. Wilson R.B. Frataxin and frataxin deficiency in Friedreich's ataxia. J Neurol Sci 207 (2003) 103-105
169. Wong A., Yang J., Cavadini P., Gellera C., Lonnerdal B., Taroni F., and Cortopassi G. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8 (1999) 425-430
170. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., Brown R., Maxwell M., Schapira A., Orntoft T.F., Kato K., and Rubinsztein D.C. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet 10 (2001) 1829-1845
171. Yu W., Gong J.S., Ko M., Garver W.S., Yanagisawa K., and Michikawa M. Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function. J Biol Chem 280 (2005) 11731-11739
172. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
173. Zhou Z., and Kang Y.J. Cellular and subcellular localization of catalase in the heart of transgenic mice. J Histochem Cytochem 48 (2000) 585-594